12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet pirfenidone regulatory update

InterMune said France's Comite Economique des Produits de Sante (CEPS) will reimburse Esbriet pirfenidone to treat idiopathic pulmonary fibrosis (IPF). The company plans to launch the product in France next quarter. InterMune said the reimbursed price corresponds to €25,000 ($31,970) per patient annually. In April, Transparency Commission (CT)...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >